(Q44371744)

2 December 2017

title

Levetiracetam for benign epilepsy of childhood with centrotemporal spikes-three cases (English)

1 reference

2 December 2017

1 reference

Luis E Bello-Espinosa

series ordinal

1

1 reference

2 December 2017

Summer L Roberts

series ordinal

2

1 reference

2 December 2017

publication date

1 April 2003

1 reference

Seizure-European Journal of Epilepsy

2 December 2017

published in

1 reference

2 December 2017

volume

12

1 reference

2 December 2017

issue

3

1 reference

2 December 2017

page(s)

157-159

1 reference

Drug treatment of benign focal epilepsies of childhood

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900004-9

7 January 2021

Lamotrigine monotherapy in children

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900004-9

7 January 2021

Risk factors for sudden unexpected death in epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900004-9

7 January 2021

The place of levetiracetam in the treatment of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900004-9

7 January 2021

Use of levetiracetam in special populations

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900004-9

7 January 2021

Carbamazepine-induced skin rash in children with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900004-9

7 January 2021

Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900004-9

7 January 2021

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900004-9

7 January 2021

Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900004-9

7 January 2021

10.1016/S1059-1311(03)00004-9

Identifiers

DOI

1 reference

2 December 2017

1 reference